Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.